Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Everolimus plus Cisplatin in TNBC with Residual Disease
NCT01931163Phase 2Completed
- Start
- Jul 2013
- Primary completion
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of everolimus in triple-negative breast cancer (TNBC). Primary endpoint: Tumor Response at 12 weeks. Started Jul 2013; status: completed.
02
Drugs
everolimus
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT01931163.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01931163.